Guest guest Posted November 21, 2002 Report Share Posted November 21, 2002 Hey Terry, for some reason my stupid email program cuts off punctuation here and there in my letters. Here it is again: http://community.healthgate.com/GetContent asp?siteid=iHerb&docid=/tnp/pg000204 there is a dot (.) after the GetContent and before the asp? And here is the entire page for you in case you still can't get to it: Herbs & Supplements: Carnitine Supplement Forms / Alternate Names • L-Carnitine, L-Acetyl-Carnitine (LAC), Propionyl L-Carnitine, Acetyl-L-Carnitine (ALC) Principal Proposed Uses • Angina and Other Heart Conditions, Intermittent Claudication, Chronic Obstructive Pulmonary Disease, Alzheimer's Disease, Depression in the Elderly, Hyperthyroidism, Peyronie’s Disease Other Proposed Uses • Hyperactivity in Fragile X Syndrome, Diabetes, Diabetic Cardiac Autonomic Neuropathy, High Cholesterol, Chronic Fatigue Syndrome, Impaired Sperm Motility, Toxicity Due to AZT, Performance Enhancement, Irregular Heartbeat, Down's Syndrome, Muscular Dystrophy, Alcoholic Fatty Liver Disease Carnitine is an amino acid the body uses to turn fat into energy. It is not normally considered an essential nutrient because the body can manufacture all it needs. However, supplemental carnitine may improve the ability of certain tissues to produce energy. This effect has led to the use of carnitine in various muscle diseases as well as heart conditions. Sources There is no dietary requirement for carnitine. However, a few individuals have a genetic defect that hinders the body's ability to make carnitine. In addition, diseases of the liver, kidneys, or brain may inhibit carnitine production. Certain medications, especially the antiseizure drugs valproic acid (Depakene) and phenytoin (Dilantin), may reduce carnitine levels; however, whether taking extra carnitine would be helpful has not been determined.1–11 Heart muscle tissue, because of its high energy requirements is particularly vulnerable to carnitine deficiency. The principal dietary sources of carnitine are meat and dairy products, but to obtain therapeutic dosages a supplement is necessary. Therapeutic Dosages Typical dosages for the diseases described here range from 500 to 1,000 mg 3 times daily. Carnitine is taken in three forms: L-carnitine (for heart and other conditions), propionyl-L-carnitine (for heart conditions), and acetyl-L-carnitine (for Alzheimer's disease). The dosage is the same for all three forms. Therapeutic Uses Carnitine is primarily used for heart-related conditions. Some evidence suggests that it can be used along with conventional treatment for angina, to improve symptoms and reduce medication needs.12–17 When combined with conventional therapy, it may also reduce mortality rates after a heart attack.18,19 Lesser evidence suggests that it may be helpful for a condition called intermittent claudication (pain in the legs after walking due to narrowing of the arteries),20–30 as well as congestive heart failure.31–34 In addition a few studies suggest that carnitine may be useful for cardiomyopathy.35,36 Carnitine may also be helpful for improving exercise tolerance in people with chronic pulmonary obstruction disease (COPD), more commonly known as emphysema.37,38,39 Warning: You should not attempt to self-treat any of these serious medical conditions, nor should you use carnitine as a substitute for standard drugs. One study found evidence that acetyl-L-carnitine is helpful for Peyronie’s disease, a condition affecting the penis.118 Some studies have found evidence that one particular form of carnitine, acetyl-L-carnitine, might be helpful in Alzheimer's disease,40–46 but the two most recent and largest studies found no benefit.47,48 This form of carnitine has also been investigated for treatment of depression in the elderly.49,50 A genetic condition called fragile X syndrome can cause behavioral disturbances such as hyperactivity, along with mental retardation, autism, and alterations in appearance. A preliminary study of 17 boys found that acetyl-L-carnitine might help to reduce hyperactive behavior associated with this condition.51 Additionally, a preliminary study suggests that carnitine may be useful for improving blood sugar control in individuals with type 2 (adult-onset) diabetes.52 It also might help prevent diabetic cardiac autonomic neuropathy (injury to the nerves of the heart caused by diabetes).53 Weak evidence suggests that carnitine may be able to improve cholesterol and triglyceride levels,54 and also help individuals with degeneration of the cerebellum (the structure of the brain responsible for voluntary muscular movement).55 One very small study suggests carnitine may be helpful for reducing symptoms of chronic fatigue syndrome.56 One study suggests that carnitine may be of value for treating hyperthyroidism.57 Uncontrolled studies suggest that L-carnitine or acetyl-L-carnitine may be helpful for improving sperm function.58–66 Weak evidence also suggests that carnitine may be helpful for decreasing the toxicity of AZT (a drug used to treat AIDS). 67,68 Carnitine is widely touted as a physical performance enhancer, but there is no real evidence that it is effective and some research indicates that it does not work.69Little to no evidence supports other claimed benefits such as treating irregular heartbeat, Down'ssyndrome, muscular dystrophy, and alcoholic fatty liver disease. What Is the Scientific Evidence for Carnitine? Angina Carnitine might be a good addition to standard therapy for angina. In one controlled study, 200 individuals with angina (the exercise-induced variety) took either 2 g daily of L-carnitine or were left untreated. All the study participants continued to take their usual medication for angina. Those taking carnitine showed improvement in several measures of heart function, including a significantly greater ability to exercise without chest pain.70 They were also able to reduce the dosage of some of their heart medications (under medical supervision) as their symptoms decreased. Unfortunately, the results of this study can't be fully trusted, because researchers didn't use a double-blind protocol. Another trial that did use a double-blind, placebo-controlled design tested L-carnitine in 52 individuals with angina, and found evidence of benefit.71 In addition, several small studies (some of them double-blind) tested propionyl-L-carnitine for the treatment of angina, and also found evidence of benefit.72–75 Intermittent Claudication People with advanced hardening of the arteries, or atherosclerosis, often have difficulty walking due to lack of blood flow to the legs. Pain may develop after walking less than half a block. Although carnitine does not increase blood flow, it appears to improve the muscle's ability to function under difficult circumstances.76 A 12-month double-blind placebo-controlled trial of 485 patients with intermittent claudication evaluated the potential benefits of propionyl-L-carnitine.77 Participants with relatively severe disease showed a 44% improvement in walking distance as compared to placebo. However, no improvement was seen in those with mild disease. Another double-blind study followed 245 people and also found benefit.78 Similar results have been seen in most but not all other studies of L-carnitine or propionyl-L-carnitine.79–87 Propionyl-L-carnitine may be more effective for intermittent claudication than plain carnitine. Congestive Heart Failure Several small studies have found that carnitine, often in the form of propionyl-L-carnitine, can improve symptoms of congestive heart failure 88–91In one trial, benefits were maintained for 60 days after treatment with carnitine was stopped.92 After a Heart Attack Carnitine may help reduce death rate after a heart attack. In a 12-month placebo-controlled study, 160 individuals who had experienced a heart attackreceived 4 g of L-carnitine daily or placebo, in addition to other conventional medication. The mortality rate in the treated group was significantly lower than in the placebo group, 1.2% versus 12.5%, respectively. There were also improvements in heart rate, blood pressure, angina (chest pain), and blood lipids.93 A larger double-blind study of 472 people found that carnitine may improve the chances of survival if given within 24 hours after a heart attack.94 Note: Carnitine is used along with conventional treatment, not as a substitute for it. Chronic Obstructive Pulmonary Disease (COPD) Evidence from three double-blind placebo-controlled studies enrolling a total of 49 individuals suggests that L-carnitine can improve exercise tolerance in COPD, presumably by improving muscular efficiency in the lungs and other muscles.95,96,97 Alzheimer's Disease Numerous double- or single-blind studies involving a total of more than 1 400 people have evaluated the potential benefits of acetyl-L-carnitine in the treatment of Alzheimer's disease and other forms of dementia.98–109 Early studies found some evidence of benefit, although it was generally quite modest. However, the two most recent and best-designed studies found no benefit. A double-blind placebo-controlled trial that enrolled 431 participants for 1 year found no significant improvement at all in the group treated with acetyl-L-carnitine.110 A close look at the results appeared to suggest some benefit in individuals who developed Alzheimer's disease at a particularly young age. However, when this possibility was tested in a 1-year double-blind placebo-controlled trial of 229 patients with early-onset Alzheimer's, no benefits were seen.111 Mild Depression A double-blind study of 60 seniors with mild depression found that treatment with 3 g of carnitine daily over a 2-month period significantly improved symptoms as compared to placebo.112 Positive results were seen in another study as well.113 Hyperthyroidism Enlargement of the thyroid (goiter) can be due to many causes, including cancer and iodine deficiency. In some cases, thyroid enlargement occurs without any known cause, so-called benign goiter. Treatment of benign goiter generally consists of taking thyroid hormone pills. This causes the thyroid gland to become less active, and the goiter shrinks. However, there may be undesirable effects as well. Symptoms of hyperthyroidism (too much thyroid hormone) can develop, including heart palpitations, nervousness, weight loss, and bone breakdown. A double-blind, placebo-controlled trial found evidence that use of L-carnitine could alleviate many of these symptoms. This 6-month study evaluated the effects of L-carnitine in 50 women who were taking thyroid hormone for benign goiter.114 The results showed that a dose of 2 or 4 g of carnitine daily protected participants' bones and reduced other symptoms of hyperthyroidism. Carnitine is thought to affect thyroid hormone by blocking its action in cells.115 This suggests a potential concern: Carnitine might be harmful for people who have low or borderline thyroid levels to begin with. This possibility has not been well explored as yet. Peyronie’s Disease Peyronie’s disease is an inflammatory condition of the penis that develops in stages. In the first stage, penile pain occurs with erection; next, the penis becomes curved; finally, erectile dysfunction may occur. Many medications have been tried for Peyronie’s disease, with some success. One such drug is tamoxifen (better known as a treatment to prevent breast cancer recurrence.) A 3- month, double-blind study compared the effectiveness of acetyl-L-carnitine (1 gram twice daily) against tamoxifen; the study enrolled 15 men in the first stage of Peyronie’s disease and 33 men in the second stage.118 The result indicated that acetyl-L-carnitine reduced penile curvature while tamoxifen did not; the supplement also reduced pain and slowed disease progression to a greater extent than the drug. Furthermore, while the drug caused various side effectsa and the supplement caused none. Performance Enhancement A 1996 review of clinical studies concluded that no scientific basis exists for the belief that carnitine supplements enhance athletic performance.116 A few studies have found some benefit, but most have not. Safety Issues L-carnitine in its three forms appears to be quite safe. However, individuals with low or borderline-low thyroid levels should avoid carnitine because it might impair the action of thyroid hormone.117 Individuals on dialysis should not receive this (or any other supplement) without a physician's supervision. The maximum safe dosages for young children, pregnant or nursing women, or those with severe liver or kidney disease have not been established. Interactions You Should Know About If you are taking Antiseizure medications, particularly valproic acid (Depakote, Depakene) but also phenytoin (Dilantin): You may need extra carnitine. Thyroid medication: Do not take carnitine except under a physician's supervision. References 1. Hug C, McGraw CA, Bates SR, et al. Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children. J Pediatr. 1991;119:799–802. 2. Chung S, Choi J, Hyun T, et al. Alterations in the carnitine metabolism in epileptic children treated with valproic acid. J Korean Med Sci. 1997 12:553–558. 3. Melegh B, Trombitas K. Valproate treatment induces lipid globule accumulation with ultrastructual abnormalities of mitochondria in skeletal muscle. Neuropediatrics. 1997;28:257–261. 4. Zelnik N, Fridkis I, Gruener N. Reduced carnitine and antiepileptic drugs: cause relationship or co-existence? Acta Paediatr. 1995;84:93–95. 5. Coulter DL. Carnitine deficiency in epilepsy: risk factors and treatment. J Child Neurol. 1995;10(suppl 2):S32–S39. 6. Melegh B, Pap M, Morava E, et al. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J Pediatr. 1994;125:317–321. 7. De Vivo DC, Bohan TP, Coulter DL, et al. L-carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia. 1998;13:1216–1225. 8. Matsuda I, Ohtani Y. Carnitine status in Reye and Reye-like syndromes. Pediatr Neurol. 1986;2:90–94. 9. Camina MF, Rozas I, Gomez M, et al. Short-term effects of administration of anticonvulsant drugs on free carnitine and acylcarnitine in mouse serum and tissues. Br J Pharmacol. 1991;103:1179–1183. 10. -Segade S, de la Pena CA, Tutor JC, et al. Carnitine deficiency associated with anticonvulsant therapy. Clin Chim Acta. 1989;181:175–181. 11. Ater SB. A developmental center population treated with VPA and L-carnitine. In: Update 1993: inborn errors of metabolism in the patient with epilepsy. Sigma-Tau Pharmaceuticals; 1993. 12. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17:225–235. 13. Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol. 1994;74:125–130. 14. Bartels GL, Remme WJ, den Hartog FR, et al. Additional anti-ischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther. 1995;9:749–753. 15. Bartels GL, Remme WJ, Holwerda KJ, et al. Anti-ischaemic efficacy of L-propionyl-carnitine—a promising novel metabolic approach to ischaemia? Eur Heart J. 1996;17:414–420. 16. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985 23:569–572. 17. Lagioia R, Scrutinio D, Mangini SG, et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol. 1992;34:167–172. 18. Davini P, Bigalli A, Lamanna F, et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18:355–365 19. Iliceto S, Scrutinio D, Bruzzi P, et al. Effect of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26:380–387. 20. Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol. 1995;26:1411–1416. 21. Bolognesi M, Amodio P, Merkel C, et al. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol. 1995 15:417–423. 22. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992;13:251–255. 23. Greco AV, Mingrone G, Bianchi M, et al. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: Controlled double blind trial versus placebo. Drugs Exp Clin Res. 1992;18:69–80. 24. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767–773. 25. Deckert J. Propionyl-L-carnitine for intermittent claudication. J Fam Pract. 1997;44:533–534. 26. Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994;15:1348–1352. 27. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther. 1991;13:2–21. 28. Brevetti G, Attisano T, Perna S, et al. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. Angiology. 1989;40:857–862. 29. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999 34:1618–1624. 30. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110:616–622. 31. Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction Eur Heart J. 1994;15:1267–1273. 32. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung. 1992;42:1101–1104. 33. Pucciarelli G, Mastursi M, Latte S, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure [in Italian; English abstract]. Clin Ter. 1992;141:379–384. 34. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17:225–235. 35. Winter S, Jue K, Prochazka J, et al. The role of L-carnitine in pediatric cardiomyopathy. J Child Neurol. 1995;10(suppl 2):S45–S51. 36. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther. 1991;13:2–21. 37. Dal Negro R, Pomari G, Zoccatelli O, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabolic and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol. 1986 24:453–456. 38. Dal Negro R, Turco P, Pomari C, et al. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol. 1988;26:269–272. 39. Dal Negro R, Zoccatelli D, Pomari C, et al. L-carnitine and physiokinesiotherapy in chronic respiratory insufficiency. Preliminary results. Clin Trials J. 1985;22:353–360. 40. Passeri M, Cucinotta D, Bonati PA, et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res. 1990;10:75–79. 41. Calvani M, Carta A, Caruso G, et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease. Ann N Y Acad Sci. 1992 663:483–486. 42. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol. 1992;49:1137–1141. 43. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology. 1991;41:1726–1732. 44. Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther. 1990;12:306–314. 45. Vecchi GP, Chiari G, Cipolli C, et al. Acetyl-l-carnitine treatment of mental impairment in the elderly: evidence from a multicenter study. Arch Gerontol Geriatr. 1991;(suppl 2):159–168. 46. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol. 1986 24:511–516. 47. Thal LJ, Carta A, e WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47:705–711. 48. Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 2000;55:805–810. 49. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res. 1990;10:355–360. 50. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res. 1990;16:101–106. 51. Torrioli MG, Vernacotola S, tti P, et al. Double-blind, placebo-controlled study of L-acetylcarnitine for the treatment of hyperactive behavior in fragile X syndrome. Am J Med Genet. 1999;87:366–368. 52. Mingrone G, Greco AV, Capristo E, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr. 1999;18:77–82. 53. Turpeinen AK, Kuikka JT, Vanninen E, et al. Long-term effect of acetyl-L-carnitine on myocardial 123I-MIBG uptake in patients with diabetes. Clin Auton Res. 2000;10:13–16. 54. Davini P, Bigalli A, Lamanna F, et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18:355–365 55. Sorbi S, Forleo P, Fani C, et al. Double-blind, crossover, placebo-controlled clinical trial with L-acetylcarnitine in patients with degenerative cerebellar ataxia. Clin Neuropharmacol. 2000;23:114–118. 56. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology. 1997;35:16–23. 57. Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of l-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2001;86:3579–3594. 58. Loumbakis P, Anezinis P, Evangeliou A, et al. Effect of L-carnitine in patients with asthenospermia [abstract]. Eur Urol. 1996;30(suppl 2):255. 59. Muller-Tyl E, Lohninger A, Fischl F, et al. The effect of carnitine on sperm count and sperm motility [translated from German]. Fertilitat. 1988 4:1–4. 60. Micic S, Lalic N, Nale DJ, et al. Effects of L-carnitine on sperm motility and number in infertile men [abstract]. Fertil Steril. 1998;70(3 suppl 1):S12. 61. Vicari E. Effectiveness of a short-term anti-oxidative high-dose therapy on IVF program outcome in infertile male patients with previous excessive sperm Radical Oxygen Species production persistent even following antimicrobials administered for epididymitis: preliminary results. In: International Meeting on Infertility and Assisted Reproductive Technology, Porto Cervo, Italy, June 11–14, 1997. Bologna, Italy: Monduzzi Editore SpA; 1997. 62. Vicari E, Cerri L, Cataldo T, et al. Effectiveness of single and combined antioxidant therapy in patients with astheno-necrozoospermia from non-bacterial epididymitis: effects after acetyl-carnitine or carnitine-acetyl-carnitine. Presented at: 12th National Conference, Italian Andrology Association; June 9–12, 1999; Copanello (CZ), Italy. 63. Campaniello E, Petrarolo N, Meriggiola MC, et al. Carnitine administration in asthenospermia. Presented at: 4th International Congress of Andrology; May 14–18, 1989; Florence, Italy. 64. Costa M, Canale D, Filicori M, et al. L-carnitine in idiopathic asthenozoospermia: a multicenter study. Andrologia. 1994;26:155–159. 65. Vitali G, Parente R, Melotti C. Carnitine supplementation in human idiopathic asthenospermia: clinical results. Drugs Exp Clin Res. 1995 21:157–159. 66. Moncada ML, Vicari E, Cimino C, et al. Effect of acetylcarnitine treatment in oligoasthenospermic patients. Acta Eur Fertil. 1992;23:221–224. 67. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. Lab Invest. 1994;71:102–112. 68. Dalakas MC, Leon-Monzon ME, Bernardini I, et al. Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol. 1994;35:482–487. 69. Heinonen OJ. Carnitine and physical exercise. Sports Med. 1996 22:109–132. 70. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17:225–235. 71. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985 23:569–572. 72. Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol. 1994;74:125–130. 73. Bartels GL, Remme WJ, den Hartog FR, et al. Additional anti-ischemic effects of long-term L-propionylcarnitine in anginal patients treated with conventional antianginal therapy. Cardiovasc Drugs Ther. 1995;9:749–753. 74. Bartels GL, Remme WJ, Holwerda KJ, et al. Anti-ischaemic efficacy of L-propionyl-carnitine—a promising novel metabolic approach to ischaemia? Eur Heart J. 1996;17:414–420. 75. Lagioia R, Scrutinio D, Mangini SG, et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol. 1992;34:167–172. 76. Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994;15:1348–1352. 77. Brevetti G, Diehm C, Lambert D. European multicenter study on propionyl-L-carnitine in intermittent claudication. J Am Coll Cardiol. 1999 34:1618–1624. 78. Brevetti G, Perna S, Sabba C, et al. Propionyl-L-carnitine in intermittent claudication: Double-blind, placebo-controlled, dose titration, multicenter study. J Am Coll Cardiol. 1995;26:1411–1416. 79. Bolognesi M, Amodio P, Merkel C, et al. Effect of 8-day therapy with propionyl-L-carnitine on muscular and subcutaneous blood flow of the lower limbs in patients with peripheral arterial disease. Clin Physiol. 1995 15:417–423. 80. Brevetti G, Perna S, Sabba C, et al. Superiority of L-propionylcarnitine vs L-carnitine in improving walking capacity in patients with peripheral vascular disease: an acute, intravenous, double-blind, cross-over study. Eur Heart J. 1992;13:251–255. 81. Greco AV, Mingrone G, Bianchi M, et al. Effect of propionyl-L-carnitine in the treatment of diabetic angiopathy: Controlled double blind trial versus placebo. Drugs Exp Clin Res. 1992;18:69–80. 82. Brevetti G, Chiariello M, Ferulano G, et al. Increases in walking distance in patients with peripheral vascular disease treated with L-carnitine: a double-blind, cross-over study. Circulation. 1988;77:767–773. 83. Deckert J. Propionyl-L-carnitine for intermittent claudication. J Fam Pract. 1997;44:533–534. 84. Sabba C, Berardi E, Antonica G, et al. Comparison between the effect of L-propionylcarnitine, L-acetylcarnitine and nitroglycerin in chronic peripheral arterial disease: a haemodynamic double blind echo-Doppler study. Eur Heart J. 1994;15:1348–1352. 85. Pepine CJ. The therapeutic potential of carnitine in cardiovascular disorders. Clin Ther. 1991;13:2–21. 86. Brevetti G, Attisano T, Perna S, et al. Effect of L-carnitine on the reactive hyperemia in patients affected by peripheral vascular disease: a double-blind, crossover study. Angiology. 1989;40:857–862. 87. Hiatt WR, Regensteiner JG, Creager MA, et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med. 2001;110:616–622. 88. Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction Eur Heart J. 1994;15:1267–1273. 89. Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung. 1992;42:1101–1104. 90. Pucciarelli G, Mastursi M, Latte S, et al. The clinical and hemodynamic effects of propionyl-L-carnitine in the treatment of congestive heart failure [in Italian; English abstract]. Clin Ter. 1992;141:379–384. 91. Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise-induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17:225–235. 92. Loster H, Miehe K, Punzel M, et al. Prolonged oral L-carnitine substitution increases bicycle ergometer performance in patients with severe ischemically induced cardiac insufficiency. Cardiovasc Drugs Ther. 1999 13:537–546. 93. Davini P, Bigalli A, Lamanna F, et al. Controlled study on L-carnitine therapeutic efficacy in post-infarction. Drugs Exp Clin Res. 1992;18:355–365 94. Iliceto S, Scrutinio D, Bruzzi P, et al. Effect of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26:380–387. 95. Dal Negro R, Pomari G, Zoccatelli O, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabolic and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol. 1986 24:453–456. 96. Dal Negro R, Turco P, Pomari C, et al. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol. 1988;26:269–272. 97. Dal Negro R, Zoccatelli D, Pomari C, et al. L-carnitine and physiokinesiotherapy in chronic respiratory insufficiency. Preliminary results. Clin Trials J. 1985;22:353–360. 98. Calvani M, Carta A, Caruso G, et al. Action of acetyl-L-carnitine in neurodegeneration and Alzheimer's disease. Ann N Y Acad Sci. 1992 663:483–486. 99. Cipolli C, Chiari G. Effects of L-acetylcarnitine on mental deterioration in the aged: initial results [in Italian; English abstract]. Clin Ter. 1990;132(6 suppl):479–510. 100. Passeri M, Cucinotta D, Bonati PA, et al. Acetyl-L-carnitine in the treatment of mildly demented elderly patients. Int J Clin Pharmacol Res. 1990;10:75–79. 101. Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the elderly. Drugs Exp Clin Res. 1994;20:169–176. 102. Spagnoli A, Lucca U, Menasce G, et al. Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology. 1991;41:1726–1732. 103. Vecchi GP, Chiari G, Cipolli C, et al. Acetyl-l-carnitine treatment of mental impairment in the elderly: evidence from a multicenter study. Arch Gerontol Geriatr. 1991;(suppl 2):159–168. 104. Thal LJ, Carta A, e WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47:705–711. 105. Campi N, Todeschini GP, Scarzella L. Selegiline versus L-acetylcarnitine in the treatment of Alzheimer-type dementia. Clin Ther. 1990;12:306–314. 106. Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Arch Neurol. 1992;49:1137–1141. 107. Rai G, G, L, et al. Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr Med Res Opin. 1990;11:638–647. 108. Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine therapy in the senile brain. Int J Clin Pharmacol Ther Toxicol. 1986 24:511–516. 109. Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 2000;55:805–810. 110. Thal LJ, Carta A, e WR, et al. A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology. 1996;47:705–711. 111. Thal LJ, Calvani M, Amato A, et al. A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology. 2000;55:805–810. 112. Bella R, Biondi R, Raffaele R, et al. Effect of acetyl-L-carnitine on geriatric patients suffering from dysthymic disorders. Int J Clin Pharmacol Res. 1990;10:355–360. 113. Garzya G, Corallo D, Fiore A, et al. Evaluation of the effects of L-acetylcarnitine on senile patients suffering from depression. Drugs Exp Clin Res. 1990;16:101–106. 114. Benvenga S, Ruggeri RM, Russo A, et al. Usefulness of l-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2001;86:3579–3594. 115. Benvenga S, Lakshmanan M, Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid. 2000 10:1043–1050. 116. Heinonen OJ. Carnitine and physical exercise. Sports Med. 1996 22:109–132. 117. Benvenga S, Lakshmanan M, Trimarchi F. Carnitine is a naturally occurring inhibitor of thyroid hormone nuclear uptake. Thyroid. 2000 10:1043–1050. 118. Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int. 2001;88:63-67. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.